Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

TESTICULAR CANCER

Can circulating microRNAs solve clinical dilemmas in testicular germ cell malignancy?

Current clinical issues in testicular germ cell tumour management include limited sensitivity and specificity of conventional biomarkers and, therefore, reliance on serial CT imaging in follow-up monitoring, as well as poor ability to risk stratify patients. Circulating microRNAs are likely to help overcome these challenges and, importantly, could offer cost savings to health-care systems.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Fig. 1

References

  1. Charytonowicz, D. et al. A cost analysis of non-invasive blood-based microRNA testing versus CT scans for follow-up in patients with testicular germ cell tumors. Clin. Genitourin. Cancer https://doi.org/10.1016/j.clgc.2019.03.015 (2019).

    Article  PubMed  Google Scholar 

  2. Dieckmann, K. P. et al. Serum levels of microRNA-371a-3p (M371 test) as a new biomarker of testicular germ cell tumors: results of a prospective multicentric study. J. Clin. Oncol. 37, 1412–1423 (2019).

    Article  Google Scholar 

  3. Murray, M. J. & Coleman, N. MicroRNA dysregulation in malignant germ cell tumors: more than a biomarker? J. Clin. Oncol. 37, 1432–1435 (2019).

    Article  Google Scholar 

  4. Murray, M. J., Huddart, R. A. & Coleman, N. The present and future of serum diagnostic tests for testicular germ cell tumours. Nat. Rev. Urol. 13, 715–725 (2016).

    Article  CAS  Google Scholar 

  5. Palmer, R. D. et al. Malignant germ cell tumors display common microRNA profiles resulting in global changes in expression of messenger RNA targets. Cancer Res. 70, 2911–2923 (2010).

    Article  CAS  Google Scholar 

  6. Murray, M. J. et al. Identification of microRNAs from the miR-371~373 and miR-302 clusters as potential serum biomarkers of malignant germ cell tumors. Am. J. Clin. Pathol. 135, 119–125 (2011).

    Article  CAS  Google Scholar 

  7. Gillis, A. J. et al. Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. Mol. Oncol. 7, 1083–1092 (2013).

    Article  CAS  Google Scholar 

  8. Hindson, C. M. et al. Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat. Methods 10, 1003–1005 (2013).

    Article  CAS  Google Scholar 

  9. Murray, M. J. et al. A pipeline to quantify serum and cerebrospinal fluid microRNAs for diagnosis and detection of relapse in paediatric malignant germ-cell tumours. Br. J. Cancer 114, 151–162 (2016).

    Article  CAS  Google Scholar 

  10. Murray, M. J. et al. “Future-proofing” blood processing for measurement of circulating miRNAs in samples from biobanks and prospective clinical trials. Cancer Epidemiol. Biomarkers Prev. 27, 208–218 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors thank St. Baldrick’s Foundation (reference 358099) and the Isaac Newton Trust (reference 15.40f) for grant funding and are grateful for financial support from the Max Williamson Fund and from C. Hodson and A. Hodson, in memory of their daughter Olivia.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Matthew J. Murray or Nicholas Coleman.

Ethics declarations

Competing interests

N.C. declares royalties from patents licensed by Becton Dickinson from Cancer Research Technology (UK) relating to the use of minichromosome maintenance proteins as biomarkers for cancer diagnosis. M.J.M. declares no competing interests.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Murray, M.J., Coleman, N. Can circulating microRNAs solve clinical dilemmas in testicular germ cell malignancy?. Nat Rev Urol 16, 505–506 (2019). https://doi.org/10.1038/s41585-019-0214-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-019-0214-2

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer